|
Published by: Global Markets Direct
Published: Jul. 31, 2011 - 86 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Arthritis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Arthritis
- Arthritis Therapeutics under Development by Companies
- Arthritis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Arthritis Therapeutics - Products under Development by Companies
- Arthritis Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Arthritis Therapeutics Development
- Johnson & Johnson
- Seikagaku Corporation
- Targeted Genetics Corporation
- Cytokine PharmaSciences, Inc.
- Novartis AG
- Daewoong Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Zydus Cadila Healthcare Limited
- Bone Medical Limited
- AnaMar Medical AB
- CREABILIS Therapeutics S.r.l.
- PLx Pharma Inc.
- TissueGene, Inc.
- Endocyte, Inc.
- NasVax Ltd.
- Zeltia, S.A.
- Kemin Industries, Inc.
- Cellceutix Pharmaceuticals, Inc.
- Arthritis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- CP-690,550 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ACZ885 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DWJ502 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Stelara - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tgAAC94 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TissueGene-C - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- KM 278 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ZYD1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MX-4042 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Piroxicam - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Meloxicam - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL 5100 Diclofenac - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL 3100 Naproxen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL 3100 Naproxen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL 1100 Ibuprofen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- KPE06001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- EC0746 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Orfadin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CT340 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug For Arthritis - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MIF Inhibitors - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DIS-BIO-OA01 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Core targeted therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Humanized antibody conjugate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Oral Anti-aCD3 Mab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BN005 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BN008 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NanoActive Indomethacin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HZN-602 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- 5-HT2 Receptor Antagonist - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Arthritis Therapeutics - Drug Profile Updates
- Arthritis Therapeutics - Discontinued Products
- Arthritis - Featured News
- Jun 23, 2011: Idera Pharmaceuticals Presents Mechanism Of Action Data Of IMO-3100 In Preclinical Model Of Arthritis At FOCIS 2011 Annual Meeting
- Jun 22, 2011: FDA Panel Rejects Novartis Drug ACZ885 For Gouty Arthritis Indication
- May 25, 2011: Novartis Announces Positive Results From Two Pivotal Phase III Trials Of ACZ885 In Patients With Severe Gouty Arthritis
- Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA
- Aug 06, 2010: Galapagos Initiates Phase I Study Of GLPG0634 In Arthritis Patients
- Oct 19, 2009: Celgene Corporation Presents Results Of Phase II Trial Study Of Apremilast In Adult Patients With Psoriatic Arthritis
- Feb 09, 2009: Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application For Novel Treatment Of Arthritis Using RPI-78
- Feb 06, 2009: PLx Receives $0.73 Million In Funding From US Army In SBIR Phase II Award
- Nov 28, 2008: Aarhus-Based Biotech Company Develops New Rheumatoid Arthritis Therapy
- Nov 04, 2008: Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Arthritis, Q3 2011
- Products under Development for Arthritis - Comparative Analysis, Q3 2011
- Number of Products under Development by Companies, Q3 2011
- Number of Products under Investigation by Universities/Institutes, Q3 2011
- Comparative Analysis by Late Stage Development, Q3 2011
- Comparative Analysis by Mid Clinical Stage Development, Q3 2011
- Comparative Analysis by Early Clinical Stage Development, Q3 2011
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
- Products under Development by Companies, Q3 2011
- Products under Development by Companies, Q3 2011
- Products under Investigation by Universities/Institutes, Q3 2011
- Johnson & Johnson, 2011
- Seikagaku Corporation, 2011
- Targeted Genetics Corporation, 2011
- Cytokine PharmaSciences, Inc., 2011
- Novartis AG, 2011
- Daewoong Pharmaceutical Co., Ltd., 2011
- Pfizer Inc., 2011
- Zydus Cadila Healthcare Limited, 2011
- Bone Medical Limited, 2011
- AnaMar Medical AB, 2011
- CREABILIS Therapeutics S.r.l., 2011
- PLx Pharma Inc., 2011
- TissueGene, Inc., 2011
- Endocyte, Inc., 2011
- NasVax Ltd., 2011
- Zeltia, S.A., 2011
- Kemin Industries, Inc., 2011
- Cellceutix Pharmaceuticals, Inc., 2011
- Assessment by Monotherapy Products, Q3 2011
- Assessment by Stage and Route of Administration, Q3 2011
- Assessment by Molecule Type, Q3 2011
- Arthritis Therapeutics - Drug Profile Updates
- Discontinued Products
- List of Figures
- Number of Products under Development for Arthritis, Q3 2011
- Products under Development for Arthritis - Comparative Analysis, Q3 2011
- Products under Development by Companies, Q3 2011
- Products under Investigation by Universities/Institutes, Q3 2011
- Late Stage Products, Q3 2011
- Mid Clinical Stage Products, Q3 2011
- Early Clinical Stage Products, Q3 2011
- Discovery and Pre-Clinical Stage Products, Q3 2011
- Assessment by Monotherapy Products, Q3 2011
- Assessment by Route of Administration, Q3 2011
- Assessment by Stage and Route of Administration, Q3 2011
- Assessment by Molecule Type, Q3 2011
- Assessment by Stage and Molecule Type, Q3 2011
AbstractArthritis - Pipeline Review, Q3 2011
Summary
Global Markets Direct’s, 'Arthritis - Pipeline Review, Q3 2011', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arthritis. 'Arthritis - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Arthritis.
- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Arthritis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Arthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
